Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5256—Virus expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/16011—Herpesviridae
  • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
  • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/16011—Herpesviridae
  • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
  • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the invention concerns a modified enveloped virus wherein said virus has at least one anti- tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; a pharmaceutical composition comprising same; and a method of treating cancer using same.
• T-effector cells T-effector cells
• CD8+ T cells specifically cytotoxic T cell lymphocytes (CTLs) are a critical component of the protective immune response against tumors.
• CTLs cytotoxic T cell lymphocytes
• This patent application describes a PeptiENV platform, which includes a novel method for coating and inserting immunomodulatory peptides onto a viral envelope which can then be readily cross-presented on antigen presenting cells.
• a viral envelope which can then be readily cross-presented on antigen presenting cells.
• WO2005/060541 teaches anti-viral peptides that are inserted into a viral coat for the purposes of disrupting the viral membrane and destroying same.
• Some viruses have viral envelopes covering their protective protein capsids.
• the envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins), but include some viral glycoproteins. They may help viruses avoid the host immune system.
• Glycoproteins on the surface of the envelope serve to identify and bind to receptor sites on the host's membrane.
• the viral envelope then fuses with the host's membrane, allowing the capsid and viral genome to enter and infect the host.
• some viruses can alternatively use endocytosis as an entry mechanism.
• a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor- specific peptide non-genetically attached to or inserted in/through the viral envelope.
• HSV-1 Herpes Simplex Virus 1
• HSV-2 Herpes Simplex Virus 2
• VSV Vaccinia Vesicular stomatitis Indiana virus
• Measles Virus Measles Virus
• Maraba virus New Castle Disease
• Reference here in to a modified enveloped virus is to a virus that is modified non-genetically to include said at least one anti-tumor, tumor-specific peptide in its viral envelope.
• said virus may or may not include any other genetic modification(s) that make(s) it suitable for its purpose but the attachment of said at least one anti-tumor, tumor- specific peptide to or through the viral envelope is undertaken non-genetically.
• viruses have viral envelopes covering their protective protein capsids.
• the envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins), but include some viral glycoproteins. They may help viruses avoid the host immune system.
• Glycoproteins on the surface of the envelope serve to identify and bind to receptor sites on the host's membrane.
• the viral envelope fuses with the host's membrane, allowing the capsid and viral genome to enter and infect the host.
• Peptides attached to or inserted in or taken through the viral envelope can thus be used as antigens to trigger an immune response.
• Reference herein to an anti-tumor peptide is to a peptide that can elicit an immune response against a tumor.
• Reference herein to a tumor-specific peptide is to a peptide that can elicit an immune response against a particular one or more tumour(s).
• said peptide is patient-identified or patient-specific.
• the exact nature of the peptide can vary having regard to the nature of the tumour to be treated, indeed the specificity of the technology means that different anti-tumor, tumor-specific peptides will be used to treat individuals presenting with different types of cancer and even different anti-tumor, tumor-specific peptides can be used to treat individuals presenting with the same type of cancer.
• said peptide is between 8-50 amino acids long, ideally 15-35 amino acids long.
• peptide has a length selected form the group comprising: 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 and 50 amino acids.
• peptides are attached to or inserted in/through the viral envelope.
• These peptides may be identical or represent the same antigen with only a minor modification i.e. greater than 90% sequence identity with each other and most ideally greater than 92%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with each other.
• a number of different anti-tumor, tumor-specific peptides are non-genetically attached to or inserted in/through the viral envelope.
• said peptide also comprises at least one cleavage site, such as, without limitation, a cathepsin cleavage site or a furin cleavage site. More preferably still, said peptide comprises at least one immunoproteoasome processing site. Examples of these sites and their relative positioning with respect to the structure of the conjugated peptide are shown in Figure 7. Ideally the one anti-tumor, tumor-specific peptide is positioned between a pair of immunoproteasome processing sites and upstream thereof is at least one cleavage site, ideally a furin cleavage site followed (upstream) by a cathepsin cleavage site.
• these peptides when attached to or inserted in/through selected enveloped viruses (HSV-1 and -2, Vaccinia, VSV, MeV, Maraba virus and NDV) can trigger increased tumor-specific immune responses and drastically enhance anti-tumor efficacy by converting the anti-viral immunity into an anti-tumor immunity.
• enveloped viruses HSV-1 and -2, Vaccinia, VSV, MeV, Maraba virus and NDV
• the elegance of this platform is that by attaching or inserting the patient-identified anti-tumor inducing tumor-specific peptides non-genetically to/in/through the viral envelope we can make clinical use of a medically approved virus. This means one can react very quickly to changes in a patients' tumor antigens that are presented on MHC-I simply by coating the virus with a new set of tumor-specific peptides derived from said patient.
• Another important feature of the invention is that the virus chosen for this platform needs to go through rigorous quality control and approval stages only once, thus saving time and money when compared to other platforms where viruses, having genetically introduced modifications, need to go through checking stages every time a new modification or a peptide is introduced, thus making it virtually impossible to use these platforms in personalized medicine.
• said peptide(s) is/are attached to or inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide (purchased from PepScan or Ontores).
• CPPs cell penetrating peptides
• This "cargo" is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions.
• the function of the CPP is to deliver the cargo into cells, a process that commonly occurs through endocytosis.
• CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively.
• a third class of CPPs are the hydrophobic peptides, containing only apolar residues, with low net charge or have hydrophobic amino acid groups that are crucial for cellular uptake.
• the invention envisages the use of any known CCP when linked with said anti-tumor, tumor- specific peptide.
• CPPs normally deliver their cargo through the lipid bilayer, a peptide consisting of a CPP sequence together with our immunogenic peptide, partially passes through the lipid bilayer while part of it appears to stick, possibly via physical hydrophobic/-philic interactions, on the membrane sufficiently, if not exclusively, for our purposes.
• cholesterol-conjugated peptides are short peptides attached to cholesterol. We have discovered that they can enter the viral envelope and so anchor the conjugated peptide within the viral coat. These peptides can be N- or C- terminally cholesterol conjugated.
• cholesterol-conjugated peptides find their "normal" location in the membrane.
• the hydroxy group on cholesterol interacts with the polar head groups of the membrane phospholipids and sphingolipids, while the bulky steroid and the hydrocarbon chain are embedded in the membrane, alongside the nonpolar fatty-acid chain of the other lipids.
• An example of a cholesterol-conjugated peptide is shown in Figure 7A.
• the peptide for attaching to or inserting in/through said envelope comprises:
• GRKKRRQRRRPQ (SEQ ID NO: 1 ) CPP sequence in the N- or C-terminus of the said anti- tumor, tumor-specific peptide
• RQIKIWFQNRRMKWKK (SEQ ID NO: 2) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide
• KLALKLALKALKAALKLA (SEQ ID NO: 3) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;
• RRRRRRRRR (SEQ ID NO: 4) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide
• KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 5) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;
• AGYLLGKINLKALAALAKKIL (SEQ ID NO: 6) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide;
• AGLWRALWRLLRSLWRLLWRA (SEQ ID NO: 7) CPP sequence in the N- or C-terminus of the said anti-tumor, tumor-specific peptide; or
• the peptide for attaching to or inserting in/through said envelope comprises one of the following wherein the sequence SIINFEKL is simply representative of a MHC-I restricted epitope or peptide:
• said anti-tumor, tumor-specific peptide(s) is/are attached to or inserted in/through said viral envelope using either a cell penetrating peptide or a cholesterol-conjugated peptide.
• virus particles were complexed with said CPP-peptide or Cholesterol-conjugated peptide by incubating same for approximately 15 min at 37 °C.
• said modified enveloped virus is provided with at least one anti-tumor, tumor-specific peptide that is MHC-I specific and so elicits an immune response ideally via MHC-I presentation on antigen presenting cells (APCs) for the activation of T-effector cells, named CD8 + T cells, specifically cytotoxic T cell lymphocytes (CTLs).
• APCs antigen presenting cells
• said modified enveloped virus is provided with at least one antitumor, tumor-specific peptide that is MHC-II specific and so elicits an immune response ideally via MHC-II presentation on antigen presenting cells (APCs) for the activation of a CD4 + (T-helper) cell response.
• APCs antigen presenting cells
• this invention also enables the use of different MHC-II epitopes coated onto the viral envelope to boost, alone or in combination with MHC-I epitopes, the immune response of the individual. Additionally or alternatively the invention also enables the use of a peptide that (s) comprise(s) a fusion molecule including a plurality of different antigens.
• viruses are selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus.
• HSV-1 Herpes Simplex Virus 1
• HSV-2 Herpes Simplex Virus 2
• Vaccinia Herpes Simplex Virus 2
• VSV Vesicular stomatitis Indiana virus
• Measles Virus Measles Virus
• Maraba virus New Castle Disease
• the invention concerns the use of two different virus types or viral backbones enabling the Prime-Boost immunovirotherapy method where the treatment with a Prime (priming) virus of a particular species/genus coated with said peptides is followed by a treatment with Boost (boosting) virus of another particular species/genus (an immunologically distinct virus) coated with the same said peptides.
• the Prime-Boost immunovirotherapy method can dramatically further increase the tumor-specific T-cell immune responses by directing the majority of the immune responses created by the Prime- Boost method towards the said peptides.
• an enveloped virus modified as herein described may be used in the Prime-Boost immunovirotherapy in combination with another enveloped virus modified as herein described but presenting the same peptides or any other virus, such as an adenovirus, that has also been modified, including genetically or non-genetically, to present the same peptides.
• HSV-1 Herpes Simplex Virus 1
• T-VEC Engineered form of HSV-1
• composition comprising:
• a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba viris and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope; and
• a method for treating a cancer comprising exposing an individual to a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor- specific peptide non-genetically attached to or inserted in/through the viral envelope.
• a modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor- specific peptide non-genetically attached to or inserted in/through the
• said method involves, after a selected period, exposing said individual to another modified enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has at least one anti-tumor, tumor-specific peptide non-genetically attached to or inserted in/through the viral envelope and further wherein said virus is different from the one used for the prior exposure.
• HSV-1 Herpes Simplex Virus 1
• HSV-2 Herpes Simplex Virus 2
• Vaccinia Vaccinia
• VSV Vesicular stomatitis Indiana virus
• Measles Virus Measles Virus
• Maraba virus New Castle Disease
• said method involves, after a selected period, exposing said individual to any another virus, such as an adenovirus, that has also been modified, including genetically or non-genetically, to present the same peptides.
• said method may be practiced by first using any virus that has been modified in any way, including genetically or non-genetically, to express selected peptides, followed by using the modified virus of the invention, having the same peptides, to provide the booster therapy.
• Prime-Boost immunovirotherapy can be practiced.
• said step of exposing an individual to a virus includes intratumoral, intranodal, intraperitoneal or intravenous injection.
• the cancer referred to herein includes any one or more pf the following cancers: nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcino
• a modified virus that expresses at least one anti-tumor, tumor-specific peptide either after exposing an individual to a modified virus that expresses at least one anti-tumor, tumor-specific peptide or after exposing said individual to an enveloped virus selected from the group comprising Herpes Simplex Virus 1 (HSV-1 ), Herpes Simplex Virus 2 (HSV-2), Vaccinia, Vesicular stomatitis Indiana virus (VSV), Measles Virus (MeV), Maraba virus and New Castle Disease (NDV) virus wherein said virus has the same or a majority of the same of said peptide(s) non-genetically attached to or inserted in/through the viral envelope, exposing said individual to a checkpoint inhibitor.
• the check point inhibitor inhibits immune checkpoint molecules such as PD-1 , PD-L1 and CTLA-4,
• Figure 1 is a summary of the data we have obtained when the anti-tumor, tumor-specific peptide is attached to different viral envelopes using either a CPP or a cholesterol- conjugated peptide;
• FIG. 2 shows CPP-containing peptides can be attached to the envelope of Herpes Simplex Virus 1 .
• CPP containing and FITC-labelled peptide was complexed with HSV-1 and a sandwich ELISA was used for detection of the complexes.
• An anti-HSV-1 antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complex.
• Figure 2 lower panel shows CPP-containing peptides have reduced diffusion time when complexed with HSV-1. Fluorescence correlation spectroscopy was used to analyze the diffusion kinetics of peptides complexed with HSV-1.
• FIG 3 upper panel shows cholesterol-containing peptides can be attached to the envelope of Vaccinia virus.
• Cholesterol-containing and FITC-labelled peptides were complexed with Vaccinia virus. After the purification of the PeptiENV complexes by 36% sucrose cushion and ultracentrifugation, the purified complexes were analyzed by flow cytometry.
• Figure 3 middle panel shows cholesterol- containing peptides can be attached to the envelope of Vaccinia virus.
• FIG. 4 upper panel shows CPP-containing peptides can be attached to the envelope of Vaccinia virus.
• CPP-containing and FITC-labelled peptides were complexed with Vaccinia virus. After the purification of the PeptiENV complexes by 36% sucrose cushion and ultracentrifugation, the purified complexes were analyzed by flow cytometry.
• Figure 4 middle panel shows CPP-containing peptides can be attached to the envelope Vaccinia virus.
• Figure 5 upper panel shows PeptiENV can induce DC activation even with very low virus amount.
• Vaccinia virus was complexed with CPP- or cholesterol-containing SIINFEKL- peptides and used for infection of mouse splenocytes. Two hours post-infection dendritic cells were analyzed by flow cytometry for the expression of DC activation markers.
• Figure 5 lower panel shows PeptiENV can induce the presentation of specific anti-tumor MHC class I epitopes by the CD1 1 c-positive DCs even with very low virus amount.
• Vaccinia virus was complexed with CPP- or cholesterol-containing SIINFEKL-peptides and used for infection of mouse splenocytes. After two hours the presentation of MHCI epitope SIINFEKL by CD1 1 c positive DC-population was determined by flow cytometry.
• Figure 6 shows PeptiENV virus-peptide complexation has no effect on viral infectivity. Infectivity of PeptiENV was compared with normal non-complexed virus and cell viability was measured 3 days post-infection.
• Figure 7 shows a schematic presentation of A) a cholesterol-conjugated immunomodulatory peptide and B) an immunomodulatory peptide having N-terminal cell penetrating peptide sequence.
• Color code for different functional sequences of the entities In dark gray: cholesterol (A.) or cell penetrating sequence (B.). In red: cathepsin D/E cleavage site. In blue: furin cleavage site. In green: immunoproteasome processing sites. In black: the MHC-I restricted epitope.
• Figure 8 shows that a variety of different CPP-sequences can be used to attach the antitumor peptides into the viral envelope.
• CPP-containing and FITC-labelled peptides were complexed with Vaccinia virus and a sandwich ELISA was used for the detection of the complexes.
• An anti-Vaccinia virus antibody was coated to the bottom of 96-well plate and PeptiENV complexes were incubated in the wells. After washing the unbound fraction, an anti-FITC HRP-conjugated antibody was used for the detection of the PeptiENV complexes.
• Figure 9 shows CPP-containing peptides do not have any antiviral effects and can be safely attached to the viral envelope without loss of infectivity or oncolytic effect.
• Figure 10 shows anti-tumour peptides anchored into viral envelope by CPP- or Cholesterol moieties induce extensive anti-tumor immunity leading to enhanced control of tumor growth and longer survival.
• A Comparison of tumor growth between groups of Mock (treated with injection media only), Vaccinia virus only, PeptiENV with anti-tumor peptides attached to the viral envelope with a cholesterol moiety (PeptiENV VACV/chol) and PeptiENV with anti- tumor peptides attached to the viral envelope with a CPP moiety (PeptiENV VACV/cpp).
• PeptiENV VACV/chol PeptiENV with anti- tumor peptides attached to the viral envelope with a CPP moiety
• Figure 11 shows PeptiENV VACV/chol and PeptiENV VACV/cpp treated mice elicit strong anti-tumor immune response and are protected from tumor rechallenge while Mock-treated mice are not protected. 500 000 B16-OVA cells were injected into the opposite flank of the previous tumor implantation and mice where followed for 14 days. No tumor growth was observed in mice treated with PeptiENV while the tumor incidence was 100% in the Mock treated group.
• Figure 12 shows anti-tumor peptides anchored into Herpes simplex virus 1 (HSV-1 ) envelope by CPP moiety induce strong anti-tumor immunity leading to enhanced control of tumor growth.
• A. Tumor growth curve of PeptiENV HSV-1/cpp, HSV-1 only and Mock treated groups.
• B Flow cytometric analysis of tumor-specific T-cells in treated tumor. PeptiENV can induce extensive filtration of tumor-specific effector T-cells in to the tumor microenvironment.
• Figure 13 shows surface plasmon resonance (SPR) measurements to confirm the high affinity of CPP-containing anti-tumor peptides to the viral envelope.
• SPR surface plasmon resonance
• Human lung carcinoma cell line A549, African Green monkey kidney epithelial cell line Vero (B) and Murine melanoma cell lines B16/OVA and B16-F10 were cultured in DMEM with 10% foetal calf serum (FBS) (Life Technologies) 1 % L-glutamine and 1 % penicillin/streptomycin at 37 °C/ 5% C02.
• Human triple negative breast cancer cell line MDMBA436 was cultured in RPMI with 10% foetal calf serum (FBS) (Life Technologies) 1 % L-glutamine and 1 % penicillin/streptomycin at 37 °C/ 5% C02.
• Herpes simplex virus 1 was produced in Vero cells and purified with sucrose gradient ultracentrifugation and eluted in 20 mM MES, 100 mM NaCI, 30 mM Tris-HCI (pH 7.2).
• VVDD-mDAI-RFP Western reserve strain of Vaccinia virus
• Vaccinia virus particles were complexed with 8ug of either CPP-peptide-FITC or cholesterol-conjugated peptide-FITC in 10Oul of DMEM for 15 min at 37 °C. After complexation, unbound peptides were removed by ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion in 1 mM Tris (pH 9.0). For ELISA, anti-Vaccinia polyclonal antibody (Abeam) was coated o/n at 4 °C into maxisorb 96-well immunoplates at the concentration of 2ug/ml.
• Abeam anti-Vaccinia polyclonal antibody
• Vaccinia-peptide complexes were incubated for 30-60min at 37 °C or RT and washed with 1xPBS for three times. Complexes were detected with anti-FITC antibody conjugated to horseradish peroxidase (Abeam) (1 :5000 dilution in 2%BSA-PBS). 2,5x107 Herpes simplex 1 virus particles were complexed with 8ug of either CPP-peptide- FITC or cholesterol-conjugated peptide-FITC in 10Oul of DMEM for 15 min at 37 °C.
• anti-HSV-1 polyclonal antibody (Abeam) was coated o/n at 4 °C into maxisorb 96- well immunoplates at the concentration of 2ug/ml. HSV-1 -peptide complexes were incubated for 30-60min at 37 °C or RT and washed with 1 xPBS for three times. Complexes were detected with anti-FITC antibody conjugated to horseradish peroxidase (Abeam) (1 :5000 dilution in 2%BSA-PBS).
• Vaccinia virus particles were complexed with 24ug of either CPP-peptide-FITC or cholesterol-conjugated peptide-FITC in 200ul of DMEM for 15 min at 37 °C. After complexation, unbound peptides were removed by ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion in 1 mM Tris (pH 9.0) and eluted to 2%Formalin in PBS. After fixing, formalin was removed with another ultracentrifugation (20.000g, 40-80mins) through 36% sucrose cushion and pellet was eluted to 1x ultrapure PBS (Gibco). Flow cytometry was performed with Apogee A50 Micro Flow Cytometer (Apogee) and FITC detection was used for assessing the complexes.
• 2x106 spleenocytes in 800 ⁇ _ of 10% RPMI-1640 culture media were incubated with 200 ⁇ _ of GRKKRRQRRRPQRVRRALISLEQLESIINFEKLTEW (SEQ ID NO: 8), LEQLESI I N FEKLTEWRVRRALISC-cholesterol (SEQ ID NO: 19) or cholesterol- CRVRRALISLEQLESIINFEKLTEW (SEQ ID NO: 20) peptide dilution (0.19 ⁇ / ⁇ ).
• the vaccinia-peptide complexes were prepared as described for ELISAs. After 2 h of incubation cells were washed and stained with either APC anti-mouse H-2Kb bound to SIINFEKL or APC Mouse lgG1 , ⁇ Isotype Ctrl (BioLegend, San Diego, CA, USA), and the samples were analyzed by flow cytometry.
• Cell viability was measured using the CellTiterGlo 96 AQueous One Solution Cell Proliferation Assay (Promega), and a multi-well plate reader (Varioscan; ThermoLabsystems) to determine the luminescence of the samples.
• a sensor slide with a silicon dioxide surface was activated by 5 min of plasma treatment followed by coating with APTES ((3-aminopropyl)triethoxysilane) by incubating the sensor in 50 mM APTES in isopropanol for 4 h.
• the sensor was then washed and placed into the SPR device, and viruses were immobilized in situ on the sensor surface of the two test channels by injecting 1 .1 x10 7 pfu of VACV in PBS (pH 7.4) for approximately 12 min, followed by a 3- min wash with PBS.
• CPP-containing anti-tumor peptide or peptide without CPP sequence was then injected into both flow channels of the flow cell in parallel, with increasing peptide concentrations ranging from 1.23uM to 100uM.
• mice C57BL/6JOIaHsd-mouse strain was used in all animal experiment.
• 350000 B16-OVA-cells were injected in the right flank of mice (in rechallence experiment, cells were injected in to the left flank) and when the tumor size reached approximately 50mm 3 (10-12 days after injection) mice were treated with non-modified viruses, PeptiENV-platform, peptides only or injection media only (Mock). Mice were treated on day 0, 2 and then a booster treatment was given on day 8-10. Tumors were measured every second day until the tumor size reached the maximum allowed.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Microbiology (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Mycology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Virology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Tropical Medicine & Parasitology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57539741

Family Applications (1)

Country Status (12)

Cited By (4)

Citations (3)

Family Cites Families (22)

• 2016
  • 2016-09-27 GB GBGB1616365.1A patent/GB201616365D0/en not_active Ceased
• 2017
  • 2017-09-06 WO PCT/EP2017/072366 patent/WO2018059896A1/en not_active Ceased
  • 2017-09-06 KR KR1020197012062A patent/KR102599401B1/ko active Active
  • 2017-09-06 CA CA3035104A patent/CA3035104A1/en active Pending
  • 2017-09-06 BR BR112019005825-7A patent/BR112019005825A2/pt not_active Application Discontinuation
  • 2017-09-06 JP JP2019515292A patent/JP7258746B2/ja active Active
  • 2017-09-06 US US16/337,220 patent/US10982194B2/en active Active
  • 2017-09-06 CN CN201780056649.7A patent/CN109890957A/zh active Pending
  • 2017-09-06 EP EP17765150.2A patent/EP3519565A1/en active Pending
  • 2017-09-06 RU RU2019110407A patent/RU2760521C2/ru active
  • 2017-09-06 AU AU2017337753A patent/AU2017337753B2/en active Active
• 2019
  • 2019-04-15 ZA ZA2019/02388A patent/ZA201902388B/en unknown
• 2022
  • 2022-12-09 JP JP2022197406A patent/JP2023029997A/ja active Pending
• 2023
  • 2023-09-29 AU AU2023237201A patent/AU2023237201B2/en active Active

Patent Citations (3)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events